Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group

Ryochi Fujii, Shintaro Hashira, Yoriko Koike, Masatoshi Takimoto, Toshiaki Oka, Hajime Yoshioka, Nobutaka Sanae, Shizuo Maruyama, Seiichiro Nanri, Hironobu Akita, Keiji Jozaki, Satoshi Iwata, Yukio Iwasaki, Masahiro Tojo, Masahiro Hotta, Naoya Yamashita, Keisuke Sunakawa, Tadao Oikawa, Mitsuru Osano, Yasuo IchihashiKazuo Ishikawa, Takefumi Kanemitsu, Shiei Ri, Kensuke Shirane, Kozo Kanki, Shioko Kawai, Nobuo Saito, Susumu Nakazawa, Hajime Sato, Yuichx Hirama, Hidejiro Chikaoka, Yoshikiyo Toyonaga, Yoshiie Kurosu, Morimasa Sugita, Makoto Hori, Naoichi Iwai, Akira Sasaki, Yōichi Taneda, Fumiko Mizoguchi, Haruhi Nakamura, Tadafumi Nishimura, Toshio Takashima, Kenji Hiromatsu, Kazuo Tabuki, Yutaka Kobayashi, Yutaka Kobayashi, Tsunekazu Haruta, Kanetsu Okura, Shigekazu Kuroki, Toru Fujiwara, Kazumi Goto, Takashi Motohiro, Kōichi Tanaka, Tatsuhiko Koga, Yasushi Shimada, Naofumi Tomita, Yasutaka Sakata, Tamotsu Fujimoto, Tohru Nishiyama, Tetsuya Nakajima, Kōji Ishimoto, Kaoru Tominaga, Fumio Yamashita, Nobuhiko Takajō, Hisaaki Araki, Shōichi Imai, Takeshi Yuasa, Yoshimi Tanaka, Shin Tsugawa, Kiyotaka Nagayama, Takeo Hashimoto, Hirofumi Nakajima, Hiroshi Matsuo, Fusae Imuta, Jiro Yura, Nobuatsu Tsuruga, Syusaku Hayashi, Yukitaka Murata

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cefotaxime is a new semisynthetic cephalosporin displaying high antibacterial activity against grampositive, gram-negative and anaerobic organisms. It acts bactericidally and is stable against betalactamases. The authors investigated the usefulness of cefotaxime in the treatment of infections in mature and premature infants and the following results were obtained; The half-life of cefotaxime after i. v. administration in mature and premature infants was inversely related to age, and tended to be longer in the former than the latter although there were pronounced intersubject differences. The pharmacokinetics of cefotaxime after i. v. injection of 10 mg/kg and 20 mg/kg was dose-related. The half-life of cefotaxime after i. v. drip infusion revealed a same trend after i. v. injection. Urinary concentration and urinary recovery were directly related. Cefotaxime was effective in 92. 5% of 80 patients, consisting of 61 mature and 19 premature infants. Responder rates by the main indications treated were 100% in 19 cases of meningitis, 81.8% in 11 cases of septicemia, 88. 0% in 25 cases of respiratory tract infection, 100% in 5 cases of urinary tract infection, 100% in 3 cases of SSS syndrome, and 100% in 4 cases of phlegmon. Forty-six pathogens were isolated from 38 patients. Excluding 4 strains for which the bacteriological response was inassessable, the eradication rate against the remaining 42 strains was 78. 6%. All 6 strains of Group B Streptococcus were isolated from patients with meningitis. Cefotaxime was both clinically and bacteriologically effective in all of these cases. Cefotaxime was effective in 20 (90.9%) of 22 patients with infections refractory to other antibiotics. Diarrhea, skin rash, elevations of GOT, GPT and LDH, and leukopenia were noted in several cases, but none of these adverse reactions were problematic. Diarrhea and skin rash occurred mainly in nursing infants. Fundamental and clinical studies of cefotaxime were carried out in mature and premature infants requiring antibiotic treatment. Cefotaxime was demonstrated to be a useful antibiotic for the treatment of infections in neonates.

Original languageEnglish
Pages (from-to)309-323
Number of pages15
JournalChemotherapy
Volume31
Issue number3
DOIs
Publication statusPublished - 1983 Jan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group'. Together they form a unique fingerprint.

Cite this